← Leaderboards
Alan L. Ho
Sloan-Kettering Inst Can Research
$4,883,159
Attributed
$7,888,759
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,503,167 · 4
FDA$385,592 · 1
By mechanism
R01$7,888,759 · 5
Top collaborators
- Timothy An-Thy Chan6 shared
- Luc Gordon Trang Morris6 shared
- James A Fagin5 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- James A Fagin$27,970,638
- Timothy An-Thy Chan$21,076,830
- Luc Gordon Trang Morris$1,605,886
- Robert Michael Tuttle$1,173,231
- Sarat Chandarlapaty$10,852,142
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMalignant NeoplasmsTumorResponseResistanceMouse ModelNovel TherapeuticsMolecularExome SequencingClinical TrialsNeoplasm MetastasisNovel StrategiesSmall MoleculePharmaceutical PreparationsBiological MarkersProtocols DocumentationT-LymphocyteMalignant Neoplasm Of ThyroidOther GeneticsIodineInsightInterestKinase InhibitorPathway Interactions
Grant awards (18)
Improving efficacy of radioiodine treatment of thyroid cancer$471,416
R01 · FY2025 · CA
Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers$194,528
R01 · FY2025 · FD · contact PI
Improving efficacy of radioiodine treatment of thyroid cancer$447,845
R01 · FY2024 · CA
Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers$191,064
R01 · FY2024 · FD · contact PI
Improving efficacy of radioiodine treatment of thyroid cancer$461,989
R01 · FY2023 · CA
Improving efficacy of radioiodine treatment of thyroid cancer$461,989
R01 · FY2022 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas$455,430
R01 · FY2022 · DE
Identifying and targeting neoantigens in aggressive salivary carcinomas$506,762
R01 · FY2021 · DE
Improving efficacy of radioiodine treatment of thyroid cancer$471,416
R01 · FY2021 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas$101,802
R01 · FY2021 · DE
Identifying and targeting neoantigens in aggressive salivary carcinomas$545,430
R01 · FY2020 · DE
Identifying and targeting neoantigens in aggressive salivary carcinomas$592,082
R01 · FY2019 · DE
Identifying and targeting neoantigens in aggressive salivary carcinomas$570,903
R01 · FY2018 · DE
Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid Cancer$620,308
R01 · FY2017 · CA · contact PI
Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid Cancer$561,313
R01 · FY2016 · CA · contact PI
Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid Cancer$526,578
R01 · FY2015 · CA · contact PI
Targeting the Oncogenic Transcription Factor c-myb in Adenoid Cystic Carcinomas$328,386
R01 · FY2013 · CA · contact PI
Targeting the Oncogenic Transcription Factor c-myb in Adenoid Cystic Carcinomas$379,518
R01 · FY2012 · CA · contact PI